Join to View Full Profile
525 E 68th StFl 3New York, NY 10065
Phone+1 212-746-3481
Fax+1 212-746-6645
Dr. Arnason is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2007 - 2010
NYU Grossman School of MedicineResidency, Internal Medicine, 2004 - 2007
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2004
Certifications & Licensure
MA State Medical License 2010 - 2027
NY State Medical License 2007 - 2011
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL Start of enrollment: 2010 Jul 01
- Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma Start of enrollment: 2012 Mar 01
- Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL Start of enrollment: 2020 Oct 19
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL.Jon E Arnason, Matthew J Matasar, Stefano Luminari, David L Tucker, Dylan Sun
Blood Advances. 2025-09-03 - Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM S...Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass
Journal of Clinical Oncology. 2025-08-20 - Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia.James T Yoon, Yinglu Zhou, Mariia Mikhaleva, Daniel S Choi, Stacey M Fernandes
Blood Advances. 2025-06-10
Abstracts/Posters
- Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisoc...Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
Tandem Meetings 2023: Research Shows Favorable Results for Lymphoma SubtypesMarch 31st, 2023- Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA to Predict Long-Term OutcomesDecember 13th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
